Recommendations for Fully Vaccinated People
Research Use Only 2019-Novel Coronavirus (2019-nCoV) Real-time RT-PCR Primers and Probes
NOT FOR DIAGNOSTIC TESTING USE
Printer friendly version pdf icon[PDF]
These sequences are intended to be used for the purposes of respiratory virus surveillance and research. The recipient agrees to use them in compliance with all applicable laws and regulations. Every effort has been made to assure the accuracy of the sequences, but CDC cannot provide any warranty regarding their accuracy. The recipient can acknowledge the source of sequences in any oral presentations or written publications concerning the research project by referring to the Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Should the recipient use these sequences in the design of a diagnostic device, the device developed from these sequences and the use of primers and probes synthesized from these sequences is not authorized under CDC’s 2019-nCoV Real-Time RT-PCR Diagnostic Panel EUA. The device would be considered a new and separate test from the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel and must comply with applicable laws and regulations. CDC has extended an open right of reference to CDC’s EUA for the 2019-nCoV Real-Time RT-PCR Diagnostic Panel. Any recipient seeking FDA authorization for a device based in whole or in part on the design of the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel is welcome to reference the CDC EUA (EUA 200001) in their application.
|Name||Description||Oligonucleotide Sequence (5’>3’)||Label1||Final
|2019-nCoV_N1-F||2019-nCoV_N1 Forward Primer||GAC CCC AAA ATC AGC GAA AT||None||500nM|
|2019-nCoV_N1-R||2019-nCoV_N1 Reverse Primer||TCT GGT TAC TGC CAG TTG AAT CTG||None||500nM|
|2019-nCoV_N1-P||2019-nCoV_N1 Probe||FAM-ACC CCG CAT TAC GTT TGG TGG ACC-BHQ1||FAM, BHQ-1||125nM|
|2019-nCoV_N1-P||2019-nCoV_N1 Probe||FAM-ACC CCG CAT /ZEN/ TAC GTT TGG TGG ACC-3IABkFQ||FAM, ZEN, 3IABkFQ||125nM|
|2019-nCoV_N2-F||2019-nCoV_N2 Forward Primer||TTA CAA ACA TTG GCC GCA AA||None||500nM|
|2019-nCoV_N2-R||2019-nCoV_N2 Reverse Primer||GCG CGA CAT TCC GAA GAA||None||500nM|
|2019-nCoV_N2-P||2019-nCoV_N2 Probe||FAM-ACA ATT TGC CCC CAG CGC TTC AG-BHQ1||FAM, BHQ-1||125nM|
|2019-nCoV_N2-P||2019-nCoV_N2 Probe||FAM-ACA ATT TGC /ZEN/ CCC CAG CGC TTC AG-3IABkF||FAM, ZEN, 3IABkFQ||125nM|
|RP-F||RNAse P Forward Primer||AGA TTT GGA CCT GCG AGC G||None||500nM|
|RP-R||RNAse P Reverse Primer||GAG CGG CTG TCT CCA CAA GT||None||500nM|
|FAM – TTC TGA CCT GAA GGC TCT GCG CG – BHQ-1||FAM, BHQ-1||125nM|
|FAM-TTC TGA CCT /ZEN/ GAA GGC TCT GCG CG-3IABkFQ||FAM, ZEN, 3IABkFQ||125nM|
1TaqMan® probes are labeled at the 5′-end with the reporter molecule 6-carboxyfluorescein (FAM) and with the quencher, Black Hole Quencher 1 (BHQ-1) (Biosearch Technologies, Inc., Novato, CA) at the 3′-end. TaqMan® probes can also be labeled at the 5′-end with the reporter molecule 6- carboxyfluorescein (FAM) and with a double quencher, ZEN™ Internal Quencher positioned between the ninth (9th) and tenth (10th) nucleotide base in the oligonucleotide sequence and Iowa Black® FQ (3IABkFQ) located at the 3’-end (Integrated DNA Technologies, Coralville, IA).
Note: Oligonucleotide sequences are continually monitored to ensure performance and may be subject to future changes as the SARS-CoV-2 virus evolves.